Sensitizers and protectors in clinical oncology.
D000477:Alkylating Agents / Q000627:therapeutic use; D004999:Amifostine / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D004357:Drug Synergism; D006801:Humans; D051379:Mice; D008920:Misonidazole / Q000009:adverse effects / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000532:radiotherapy; D009593:Nitroimidazoles / Q000627:therapeutic use*; D009946:Organothiophosphorus Compounds / Q000627:therapeutic use*; D011837:Radiation-Protective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*
D000477:Alkylating Agents; D009593:Nitroimidazoles; D009946:Organothiophosphorus Compounds; D011837:Radiation-Protective Agents; D011838:Radiation-Sensitizing Agents; D008920:Misonidazole; D004999:Amifostine